Susan Halabi, PhD, discusses an analysis that found that the risk of death from metastatic castration-resistant prostate cancer was nearly 20% lower in African-American men than in Caucasian men.
Susan Halabi, PhD
Contrary to their initial hypothesis, investigators recently found that the risk of death from metastatic castration-resistant prostate cancer (mCRPC) was nearly 20% lower in African-American men than in Caucasian men, according to data presented at the 2018 ASCO Annual Meeting.
An initial analysis of African-American and Caucasian patients with metastatic castration-resistant prostate cancer demonstrated that there was no significant difference in overall survival (OS) between the 2 populations; the median OS was 21.0 and 21.2 months, respectively. However, an adjusted analysis that factored in age, prostate-specific antigen (PSA) levels, and other variables showed the risk of death was approximately 19% lower for African-American patients (HR, 0.81; 95% CI, 0.72-0.92;P= .001), explained Susan Halabi, PhD.
The study analyzed data from 9 different randomized phase III trials in which patients with mCRPC were treated with docetaxel. The data comprised 8871 men, 85% of whom were Caucasian and 6% were African American, Halabi said.
In an interview withTargeted Oncology, Halabi, a professor of Biostatistics and Bioinformatics at Duke University School of Medicine, discussed the unexpected results of this survival disparity analysis in men with mCRPC.
TARGETED ONCOLOGY:What was the rationale for this study?
Halabi:We know that in the United States, African-American men are diagnosed at a much later stage of prostate cancer. In addition, they have higher incidence rates and higher mortality rates than Caucasian men with the disease. We know that African-American men [sometimes] do not have equal access to healthcare. Based on the population data, we were interested to test our hypothesis about OS outcomes in African-American and Caucasian men. Our initial hypothesis was that African-American men will have worse survival outcomes than Caucasian men.
In order to test this, we pulled data from 9 randomized phase II trials, which comprised over 8000 men. What was really interesting was that 85% of the men were Caucasian and only 6% were African American. Nevertheless, we went ahead with our study. In our initial analysis, we found no differences between the 2 subgroups; the median OS was 21 months.
However, when we did an adjusted analysis for important variables that might affect outcomes, like age, PSA levels, etc, we found that the hazard ratio was 0.81 in favor of African-American men. What does that mean? It means that the risk of death was about 19% lower for African-American men than Caucasian men. This is contrary to our initial hypothesis.
TARGETED ONCOLOGY:What was the breakdown of demographics in the study?
Halabi:Out of the [total population], we know that 85% of them were Caucasian, 6% were African American, 5% were Asian, and 4% were other or unknown ratio groups. When we look at demographics between those patients, we found the following: African-American men were younger, had lower hemoglobin levels, had higher PSA levels, and had worse [ECOG] performance status. These were all statistically significant. Despite all the differences in terms of burden of disease, we found, to our surprise, that African-American patients did better.
TARGETED ONCOLOGY:What might be the reason for these data?
Halabi:This is an open question that we cannot answer definitively right now. This is a whole new area that requires further research. We can hypothesize or we can assume certain things. The first idea might be that African-American men have biological differences than Caucasian men. This could be why they're responding better. Remember, the patients we analyzed all received chemotherapy. It could mean that the African-American men were stronger and fitter.
It could also have to do with the patient selection. We know that to become involved with clinical trials, there is certain eligibility criteria. It could be that the clinician is using a tougher standard. Of course, we don't have data right now to support that claim. It could also mean that the African-American men generally respond better to chemotherapy than Caucasian men. No matter what, what's remarkable is the findingsand this will be a paradigm shift. When men have advanced and lethal mCRPC, we see that the African-American men are not only doing as well as Caucasian patients, but they're doing even better.
TARGETED ONCOLOGY:What are some additional analyses that will follow this study?
Halabi:We have also accessed genomic data to see if there is genomic variability between the 2 populations. What's also interestingand it's important to know—is that out of these 9 trials, only 3 of them were conducted by the National Cancer Institute’s National Clinical Trials Network. When we looked at a subgroup of patients enrolled in the United States, we saw even more striking data that African-American men are 24% less likely to die from this disease than Caucasian men. Six of these trials were also conducted globally.
One of the take-home messages here is that we need to develop new methodology to enroll more African-American men in phase III clinical trials. We need to vigorously implement this methodology so that minorities are well represented. We are also looking at the original analysis and studying progression-free survival.
TARGETED ONCOLOGY:Are there any other demographics or tumor types where there might be disparity?
Halabi:Next, we might look at Asian versus Caucasian patients and we're excited to look at that. Right now, though, we don't have access to other tumor types. It's important to emphasize that these results can't be applied to the general population because we know that only about 3% of patients with cancer in the United States enroll in clinical trials.
Halabi S, Dutta S, Tangen CM, et al. Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).J Clin Oncol. 2018;36 (suppl; abstr LBA5005).